Advertisement Opportunities | About Us | Contact Us | Tell us what you think | Jobs | Shopping | Scandinavian Dating | Archive

Scandinavian Companies and Market


Companies News

The Market Quotes Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

Medivir announces new studies in phase III program for TMC435:

Tuesday, 13 March 2012
Huddinge, Sweden – MedivirAB (OMX: MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively. See attachment for details

What do you think about this article or us? Please leave a comment. Thank you!

  • Should be Empty:

Print Friendly and PDF